Amneal Pharmaceuticals Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
20.0%projected annual EPS growth
Analyst Coverage
4analysts covering
FY Revenue (est.)
$3.1Bnext fiscal year
FY EPS (est.)
$1.00next fiscal year
Monitoring Framework
Key Performance Indicators
Consolidated Net Revenue Quarterly723MTarget: 3050000000 - 3150000000
Adjusted EBITDA Quarterly202MTarget: 740000000 - 770000000
Adjusted Diluted EPS Quarterly0.3Target: 0.95 - 1.05
Operating Cash Flow Quarterly-26.7MTarget: 350000000 - 400000000
Watch Items
- Kashiv BioSciences Acquisition IntegrationTrigger: Transaction closing expected in H2 2026Action: Monitor regulatory approvals, shareholder votes, and initial cost/operational synergy realization.
- CREXONT Commercial Rollout and Rytary Generic ErosionTrigger: Specialty segment revenue flat in 2026 due to Rytary erosionAction: Track weekly/monthly prescription uptake of CREXONT to offset Rytary generic erosion.
- Net Leverage RatioTrigger: Net leverage at 3.5x as of Q1 2026Action: Verify progress toward the company's target of deleveraging below 3.0x by 2028.
Research as of 19 Jun 2026